(S)-Crizotinib

Overview

(S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC 50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-100549
• CAS No.: 1374356-45-2
• Molecular Formula: C21H22Cl2FN5O
• Molecular Weight: 450.34
• Purity: 99.81%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 1.25 mg/mL (2.78 mM); Clear solution
• Availability: In-stock

Source

Original product source